SEC Form 4 · accession 0001209191-18-015100
XBiotech Inc. · XBIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Table I — non-derivative securities
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option | $4.83 | Feb 27, 2018 | A | 25,000 | A | Aug 27, 2018 | Feb 27, 2028 | Common Stock | 25,000 | 25,000 | D |
Remarks
Upon election as a Board Member and pursuant to the Board Member Agreement in place between Jan-Paul Waldin (the "Reporting Person") and the Company (the "Agreement"), the Reporting Person was granted non-qualified stock options to purchase 25,000 shares of the Company's common stock on February 27, 2018 (the "Grant Date"). All granted options will be exercisable at a price equal to the closing price of the Company's common stock, as reported by NASDAQ, on the Grant Date, and vest in two equal installments occurring six months and 12 months following the Grant Date, subject to continued service as a Director. The Options shall expire ten years from the Grant Date, unless terminated earlier in accordance with the Plan or the Reporting Person's stock option agreement. In accordance with the Plan, the Options will remain exercisable for 90 days after the date of the Reporting Person's termination without cause or resignation.